We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.


Normal Karyotype AML testing

Note that from 7 December 2016, testing of FLT3 has been suspended until further notice. Please contact the laboratory for further testing details.

As many patients do not have a specific translocation to facilitate MRD monitoring, we routinely monitor for NPM1 and FLT3-ITDs on the diagnostic pre-treatment sample.

This is usually done on PB alone for FLT3-ITDs and both PB and BM for NPM1.

Two separate samples are required for FLT3-ITD and NPM1 screening because the tests are carried out on DNA and RNA respectively.

Therefore to facilitate appropriate testing, 15ml EDTA PB is required for FLT3-ITD testing and a separate 15ml PB plus 2-3ml EDTA BM for NPM1 testing.